EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension

Anthony Rodgers, Abdul Salam, Aletta E Schutte, William C Cushman, H Asita de Silva, Gian Luca Di Tanna, Diederick Grobbee, Krzysztof Narkiewicz, Dike B Ojji, Neil R Poulter, Markus P Schlaich, Suzanne Oparil und 13 weitere

Journal of the American College of Cardiology · 2024-12 · 84 (24) · 2393-2403

DOI: 10.1016/j.jacc.2024.08.025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024-12. Verfasst von Anthony Rodgers und 24 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: arodgers@georgeinstitu…. Hauptthemen laut MEDLINE: Hypertension, Amlodipine, Indapamide, Antihypertensive Agents. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: European Commission, NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Single-pill combinations of 3 or more low-dose blood pressure (BP)-lowering drugs hold promise for initial or early treatment of hypertension. OBJECTIVES: The authors conducted a placebo-controlled trial of a new single-pill combination containing low doses of telmisartan, amlodipine, and indapamide in 2 dose options to assess efficacy and safety. METHODS: This international, randomized, double-blind, placebo-controlled, parallel-group trial enrolled adults with hypertension receiving 0 to 1 BP-lowering drugs. After a 2-week placebo run-in during which any BP-lowering medication was stopped, participants were eligible if home systolic BP (SBP) was 130 to 154 mm Hg. Participants were randomized in a 2:2:1 ratio to GMRx2 ¼ dose (telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg), GMRx2 ½ dose (telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg), or placebo. The primary efficacy outcome was difference in change in home SBP from randomization to week 4, and primary safety outcome was treatment discontinuation due to an adverse event. RESULTS: From June 14, 2021 to October 18, 2023, a total of 295 participants (mean age: 51 years; 56% female) were randomized and 96% completed the trial. Baseline mean home BP was 139/86 mm Hg and clinic BP was 138/86 mm Hg after placebo run-in. The placebo-corrected least square mean differences in home SBP at Week 4 were -7.3 mm Hg (95% CI: -4.5 to -10.2) for GMRx2 ¼ dose and -8.2 mm Hg (95% CI: -5.2 to -11.3) for GMRx2 ½ dose; reductions for clinic BP were 8.0/4.0 and 9.5/4.9 mm Hg. At Week 4, clinic BP control ( 150 mmol/L or potassium 6.0 mmol/L. Serious adverse events were reported by 2 participants in the placebo and GMRx2 ½ groups and none in the GMRx2 ¼ group. CONCLUSIONS: In a population with mild-to-moderate BP elevation, both dose versions of the novel low-dose triple single-pill combination showed good tolerability and clinically relevant BP reductions compared with placebo. (Efficacy and Safety of GRMx2 Compared to Placebo for the Treatment of Hypertension: NCT04518306).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionAmlodipineIndapamideAntihypertensive AgentsTelmisartanDrug CombinationsHumansMaleFemaleMiddle AgedDouble-Blind MethodTreatment OutcomeAgedBlood PressureDose-Response Relationship, DrugAdult

Stichwörter der Autor:innen

clinical trialglobal healthhypertensionpharmacotherapy

Substanzen

AmlodipineIndapamideAntihypertensive AgentsTelmisartanDrug Combinations

Autor:innen und Institutionen

  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: arodgers@georgeinstitute.org.
  • The George Institute for Global Health, University of New South Wales, Hyderabad, India.
  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
  • University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland.

Förderung

  • European Commission
  • NHMRC

Zitieren

APA

Rodgers, A., Salam, A., Schutte, A. E., Cushman, W. C., de Silva, H. A., Di Tanna, G. L., Grobbee, D., Narkiewicz, K., Ojji, D. B., Poulter, N. R., Schlaich, M. P., Oparil, S., Spiering, W., Williams, B., Wright, J. T., Gutierez, A., Sanni, A., Lakshman, P., McMullen, D., …, & Whelton, P. (2024). Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. Journal of the American College of Cardiology, 84(24), 2393-2403. https://doi.org/10.1016/j.jacc.2024.08.025

Vancouver

Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. Journal of the American College of Cardiology. 2024;84(24):2393-2403. doi:10.1016/j.jacc.2024.08.025

BibTeX
@article{Rodgers2024,
  author = {Rodgers, Anthony and Salam, Abdul and Schutte, Aletta E and Cushman, William C and de Silva, H Asita and Di Tanna, Gian Luca and Grobbee, Diederick and Narkiewicz, Krzysztof and Ojji, Dike B and Poulter, Neil R and Schlaich, Markus P and Oparil, Suzanne and Spiering, Wilko and Williams, Bryan and Wright, Jackson T and Gutierez, Alexis and Sanni, Aliu and Lakshman, Poopalan and McMullen, Deirdre and Ranasinghe, Gotabhaya and Gianacas, Chris and Shanthakumar, Mathangi and Liu, Xiaoqiu and Wang, Nelson and Whelton, Paul},
  title = {Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension},
  journal = {Journal of the American College of Cardiology},
  year = {2024},
  volume = {84},
  number = {24},
  pages = {2393--2403},
  doi = {10.1016/j.jacc.2024.08.025}
}
Kostenlos starten →